A COMPREHENSIVE ANALYSIS OF MARCH 2024 AMENDMENTS, SHORTENED REQUEST FOR EXAMINATION DEADLINES, AND FORM 27 MODIFICATIONS
AUTHOR – S.RENUKA, ASSISTANT PROFESSOR, GOVERNMENT LAW COLLEGE, TRICHY
BEST CITATION – S.RENUKA, A COMPREHENSIVE ANALYSIS OF MARCH 2024 AMENDMENTS, SHORTENED REQUEST FOR EXAMINATION DEADLINES, AND FORM 27 MODIFICATIONS, INDIAN JOURNAL OF LEGAL REVIEW (IJLR), 6 (1) OF 2026, PG. 392-408, APIS – 3920 – 0001 & ISSN – 2583-2344. DOI – https://doi.org/10.65393/BABJ6166
ABSTRACT
India’s Ministry of Commerce and Industry has, on March 15, 2024, notified the Patents (Amendment) Rules, 2024, thereby marking a major development in the Indian patent system. The amendments have made drastic changes to the patent prosecution timelines, opposition procedures, and patent working disclosure requirements. The article discusses in detail the three key changes: the shortening of Request for Examination (RFE) deadlines from 48 months to 31 months based on the priority date; the speeding up of the opposition review timelines for both pre-grant and post-grant oppositions; and the major change in the Form 27 working statement from annual to triennial filing intervals with significantly simplified information disclosure. The study’s methodology includes an in-depth legal doctrinal analysis, case law scrutiny, and a comparative approach to jurisprudence. It has evaluated the consequences of the new patent rules for patent applicants, patent holders, and public interest groups, especially in the pharmaceutical industry. The article pinpoints significant research gaps related to empirical enforcement data, compulsory licensing under Section 83-84, and access to medicines implications, while also suggesting methodological frameworks for future studies.
Keywords: Patent Rules 2024, Request for Examination, Form 27, Working Requirements, Opposition Timelines, Pharmaceutical Patents, India, Patentability, Patent Prosecution